Radioimmunoassay of acipimox in human plasma and urine
- 1 November 1984
- journal article
- research article
- Published by Elsevier in Pharmacological Research Communications
- Vol. 16 (11) , 1081-1090
- https://doi.org/10.1016/s0031-6989(84)80072-7
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Bioavailability and Pharmacokinetics in Man of Acipimox, a New Antilipolytic and Hypolipemic AgentJournal of International Medical Research, 1981
- Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) II — Antilipolytic and blood lipid lowering activityPharmacological Research Communications, 1981
- Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) I — Mechanism of actionPharmacological Research Communications, 1981
- Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, anew inhibitor of lipolysisAtherosclerosis, 1981
- Inhibition of lipolysis by nicotinic acid and by acipimoxClinical Pharmacology & Therapeutics, 1980
- A Quantitative Immunochemical Measure of thePrimary Interaction Between I*BSA and AntibodyThe Journal of Infectious Diseases, 1958